IVIG adverse reaction: Potential role of cytokines and vasoactive substances

被引:24
作者
Bagdasarian, A [1 ]
Tonetta, S [1 ]
Harel, W [1 ]
Mamidi, R [1 ]
Uemura, Y [1 ]
机构
[1] Alpha Therapeut Corp, Dept Res & Dev, Los Angeles, CA 90032 USA
关键词
D O I
10.1159/000030909
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Objectives: A clinical study was conducted to determine the effect of IVIG infusion rates on adverse experiences (AE) and on serum levels of cytokines and vasoactive substances. Materials and Methods: Forty-two healthy volunteers were randomized into 3 groups with maximum IVIG infusion rates of 0.04, 0.06, and 0.08 ml/kg/min, and a final dose of 0.5 g IgG/kg body weight, Results: Adverse reactions were noted only at the highest infusion rate of 0.08 ml/kg/min, except in 1 subject infused at 0.06 ml/kg/min. There were significant increases in IL-6 (p = 0.011) and thromboxane B-2 (p = 0.007) in AE subjects as compared to non-AE subjects. Conclusion: IVIG-induced adverse reactions occur more often with rapid infusion rates and may be mediated by elevated levels of inflammatory cytokines and vasoactive substances.
引用
收藏
页码:74 / 82
页数:9
相关论文
共 48 条
[1]   ANTI-CYTOKINE NATURE OF NATURAL HUMAN-IMMUNOGLOBULIN - ONE POSSIBLE MECHANISM OF THE CLINICAL EFFECT OF INTRAVENOUS IMMUNOGLOBULIN THERAPY [J].
ABE, Y ;
HORIUCHI, A ;
MIYAKE, M ;
KIMURA, S .
IMMUNOLOGICAL REVIEWS, 1994, 139 :5-19
[2]  
ALVING BM, 1980, J LAB CLIN MED, V96, P334
[3]   POOLED HUMAN-IGG MODULATES CYTOKINE PRODUCTION IN LYMPHOCYTES AND MONOCYTES [J].
ANDERSSON, U ;
BJORK, L ;
SKANSENSAPHIR, U ;
ANDERSSON, J .
IMMUNOLOGICAL REVIEWS, 1994, 139 :21-42
[4]   INTERACTION OF FC-RECEPTOR (CD16) LIGANDS INDUCES TRANSCRIPTION OF INTERLEUKIN-2 RECEPTOR (CD25) AND LYMPHOKINE GENES AND EXPRESSION OF THEIR PRODUCTS IN HUMAN NATURAL-KILLER CELLS [J].
ANEGON, I ;
CUTURI, MC ;
TRINCHIERI, G ;
PERUSSIA, B .
JOURNAL OF EXPERIMENTAL MEDICINE, 1988, 167 (02) :452-472
[5]  
AUKRUST P, 1994, BLOOD, V84, P2136
[6]  
BAGDASARIAN A, 1995, INT S CLIN IMM SAN F
[7]   DEVELOPMENT OF IMMUNOGLOBULIN PREPARATIONS FOR INTRAVENOUS USE [J].
BARANDUN, S ;
ISLIKER, H .
VOX SANGUINIS, 1986, 51 (02) :157-160
[8]   INTRAVENOUS ADMINISTRATION OF HUMAN GAMMA-GLOBULIN [J].
BARANDUN, S ;
JEUNET, F ;
KISTLER, P ;
ISLIKER, H .
VOX SANGUINIS, 1962, 7 (02) :157-&
[9]  
BENCHETRIT E, 1992, NEW ENGL J MED, V326, P270
[10]  
BUCKLEY RH, 1991, NEW ENGL J MED, V325, P110, DOI 10.1056/NEJM199107113250207